Liu Peng, Zhou Ming, Luo Zhisheng, Hao Lu, Hsu Jessica C, Cai Weibo, Zhou Wenhu, Hu Shuo
Department of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, China; Key Laboratory of Biological Nanotechnology, NHC, No. 87 Xiangya Road, Changsha, Hunan, 410008, China; Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Department of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, Hunan, 410008, China.
Biomaterials. 2025 Jun;317:123098. doi: 10.1016/j.biomaterials.2025.123098. Epub 2025 Jan 9.
Osteoarthritis (OA) is a prevalent and debilitating condition characterized by cartilage destruction and inflammation. Traditional pharmacotherapies for OA are limited by their short-term efficacy and systemic side effects. Radiosynoviorthesis (RSO), involving intra-articular injection of radiopharmaceuticals, has shown promise for OA treatment but is hindered by the toxicity and rapid clearance of radioisotopes. Herein, we propose a novel strategy utilizing metal-organic coordination polymers (MCPs) as carrier of radioactive Lu, with adenosine monophosphate (AMP) as ligand. We then incorporate the MCPs into chitosan/β-glycerophosphate thermosensitive hydrogels (Lu/AMP@CG), which demonstrates enhanced retention of Lu in the joint cavity. These hydrogels enable a single-dose intra-articular injection to provide sustained OA treatment without adverse effects. Combining Lu-based RSO with the pharmacological properties of chitosan-based hydrogel yields exceptional anti-inflammatory, cartilage repair and protective effects. Together, this study underscores the significant local retention capacity of the Lu/AMP@CG hydrogel and the potential of anti-inflammatory and chondroprotective strategy toward OA treatment.
骨关节炎(OA)是一种常见且使人衰弱的疾病,其特征为软骨破坏和炎症。OA的传统药物治疗受到短期疗效和全身副作用的限制。放射性滑膜切除术(RSO),即关节腔内注射放射性药物,已显示出治疗OA的前景,但受到放射性同位素的毒性和快速清除的阻碍。在此,我们提出一种新策略,利用金属有机配位聚合物(MCPs)作为放射性镥的载体,以单磷酸腺苷(AMP)作为配体。然后我们将MCPs掺入壳聚糖/β-甘油磷酸酯热敏水凝胶(Lu/AMP@CG)中,该水凝胶显示出镥在关节腔内的保留增强。这些水凝胶能够通过单次关节腔内注射提供持续的OA治疗且无不良反应。将基于镥的RSO与基于壳聚糖的水凝胶的药理特性相结合,可产生卓越的抗炎、软骨修复和保护作用。总之,本研究强调了Lu/AMP@CG水凝胶显著的局部保留能力以及抗炎和软骨保护策略对OA治疗的潜力。